AbbVie Inc (ABBV)
AbbVie Inc. is a research-based biopharmaceutical company focused on discovering, developing, manufacturing, commercializing, and selling medicines and therapies worldwide. Its portfolio includes treatments for autoimmune and inflammatory conditions, blood cancers, and solid tumors, along with products for migraine, schizophrenia, bipolar disorder, Parkinson’s disease, hepatitis C, pancreatic enzyme therapy, and irritable bowel syndrome with constipation. The company also markets aesthetic and eye care products, including facial injectables, body contouring, skincare, and therapies for elevated intraocular pressure and other ophthalmic conditions. AbbVie was incorporated in 2012 and is headquartered in North Chicago, Illinois. The listed security is common stock on the NYSE under the symbol ABBV.
Jump between the core stock analysis sections, valuation data, fair value models, technical outlook, and FAQ.
| Ticker | Fair Value | Fair Value Upside/Downside | Fair Value Rating | Analyst Price Target | Analyst Target Upside/Downside | Analyst Target Rating | Overall Financial Health | Upcoming Dividend Ex-Date | Dividend Payment Date | Upcoming Dividend | Dividend Yield | Next Earnings Date | P/E Ratio | Price-to-Book Ratio | Price-to-Sales Ratio | Market Cap | Enterprise Value | Total Debt / Total Capital | Free Float / Shares Outstanding | Altman Z-Score | Payout Ratio | Free Cash Flow / Net Income |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
NYSE-ABBV
|
$258.05
|
0.8% Upside
|
Fair
|
$266.57
|
4.2% Upside
|
Fair
|
Great
|
July 15, 2026
|
August 14, 2026
|
6.92
|
2.7%
|
July 31, 2026
|
125.6x
|
-67.8x
|
7.2x
|
447.7 B
|
515.2 B
|
14.0%
|
99.8%
|
3.9
|
325.1%
|
555.8%
|
